XORTX Therapeutics Inc. (TSXV: XRTX)
Health Care · Pharmaceuticals · CA
CA$3.09
+8.42% today · -50.4% 1Y
XORTX Therapeutics Inc. (TSXV: XRTX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.75M and employs 2 people.
Over the last twelve months the share price has lost 50.4%, trading between 2.43 and 9.85.
Tweenvest scores XORTX Therapeutics Inc. across four factors: quality 26/100. Its strongest factor is quality.
XRTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.75M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.83
- Dividend yield
- —
- Beta (5Y)
- 0.08
- 52-week high
- CA$9.85
- 52-week low
- CA$2.43
- Avg volume (3M)
- —
- Shares outstanding
- 1.82M
- Employees
- 2
- Next earnings
- —
About XORTX Therapeutics Inc.
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
- ISIN
- CA98420Q4051
- Listed since
- Nov 5, 2021
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,234.81 | +0.09% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.37 | +0.08% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.00 | -0.29% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.